Independence Bank of Kentucky’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Independence Bank of Kentucky’s Portfolio LOGC Stock Details LOGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-42,325	Closed	-$12K	–	458
2022 Q3	$12K	Hold	42,325	–	–	0.01%	331
2022 Q2	$15K	Buy	42,325 +32,125	+315%	+$16.2K	0.01%	329
2022 Q1	$7K	Sell	10,200 -2,675	-21%	-$2.94K	﹤0.01%	366
2021 Q4	$30K	Buy	+12,875	New	+$43.6K	0.01%	281

Independence Bank of Kentucky's LOGC Position: Q4 2022 in Review

Independence Bank of Kentucky sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 42,325 shares — an estimated $12K sold.

Independence Bank of Kentucky first reported a position in LOGC in Q4 2021 and held it in 4 quarters. The position peaked at $30K in Q4 2021. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.

Independence Bank of Kentucky reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Independence Bank of Kentucky sold 42,325 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $12K.
Independence Bank of Kentucky first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2021 and held it in 4 quarters.
Independence Bank of Kentucky's LogicBio Therapeutics, Inc. Common Stock position peaked at $30K in Q4 2021.
0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Independence Bank of Kentucky's 13F filing for Q4 2022, filed 9 Jan 2023.